141 related articles for article (PubMed ID: 28263279)
1. Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population.
Suarez-Kurtz G; Struchiner CJ
Pharmacogenet Genomics; 2017 May; 27(5):210-211. PubMed ID: 28263279
[No Abstract] [Full Text] [Related]
2. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm.
Li X; Liu R; Yan H; Tang J; Yin JY; Mao XY; Yang F; Luo ZY; Tan SL; He H; Chen XP; Liu ZQ; Li Z; Zhou HH; Zhang W
J Clin Pharmacol; 2015 Mar; 55(3):251-7. PubMed ID: 25187307
[TBL] [Abstract][Full Text] [Related]
3. Race influences warfarin dose changes associated with genetic factors.
Limdi NA; Brown TM; Yan Q; Thigpen JL; Shendre A; Liu N; Hill CE; Arnett DK; Beasley TM
Blood; 2015 Jul; 126(4):539-45. PubMed ID: 26024874
[TBL] [Abstract][Full Text] [Related]
4. Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
Ohara M; Suzuki Y; Shinohara S; Gong IY; Schmerk CL; Tirona RG; Schwarz UI; Wen MS; Lee MTM; Mihara K; Nutescu EA; Perera MA; Cavallari LH; Kim RB; Takahashi H
Clin Pharmacokinet; 2019 Aug; 58(8):1077-1089. PubMed ID: 30815847
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of Warfarin Therapy.
Ruff CT
Clin Chem; 2018 Nov; 64(11):1558-1559. PubMed ID: 29941467
[No Abstract] [Full Text] [Related]
6. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
7. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the impact of
Asari K; Takahashi H
Pharmacogenomics; 2020 Aug; 21(12):853-862. PubMed ID: 32700644
[No Abstract] [Full Text] [Related]
9. Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.
Peng Q; Huang S; Chen X; Yuan Y; Yu Y; Tao L; Zhang Z; Xu M
Pharmacogenomics; 2015; 16(13):1465-74. PubMed ID: 26255607
[TBL] [Abstract][Full Text] [Related]
10. Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients.
Ndadza A; Cindi Z; Makambwa E; Chimusa E; Wonkam A; Kengne AP; Ntsekhe M; Dandara C
OMICS; 2019 Jan; 23(1):36-44. PubMed ID: 30566377
[TBL] [Abstract][Full Text] [Related]
11. Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics.
Fitzgerald G; Prince C; Downing J; Reynolds J; Zhang JE; Hanson A; Alfirevic A; Pirmohamed M
Pharmacogenomics; 2019 Jun; 20(8):599-608. PubMed ID: 31046595
[No Abstract] [Full Text] [Related]
12. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from the influence of CYP2C9 genotype on warfarin dosing.
Tidbury N; Preston J; Lip GYH
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):185-188. PubMed ID: 37254883
[No Abstract] [Full Text] [Related]
14. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
[TBL] [Abstract][Full Text] [Related]
15. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
[TBL] [Abstract][Full Text] [Related]
16. Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses.
Ohara M; Takahashi H; Lee MT; Wen MS; Lee TH; Chuang HP; Luo CH; Arima A; Onozuka A; Nagai R; Shiomi M; Mihara K; Morita T; Chen YT
PLoS One; 2014; 9(8):e105891. PubMed ID: 25148255
[TBL] [Abstract][Full Text] [Related]
17. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
[TBL] [Abstract][Full Text] [Related]
18. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Hirai K; Yamada Y; Hayashi H; Tanaka M; Izumiya K; Suzuki M; Yoshizawa M; Moriwaki H; Akimoto T; Tsuji D; Inoue K; Itoh K
Thromb Res; 2015 May; 135(5):861-6. PubMed ID: 25747538
[TBL] [Abstract][Full Text] [Related]
19. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.
Santos PC; Marcatto LR; Duarte NE; Gadi Soares RA; Cassaro Strunz CM; Scanavacca M; Krieger JE; Pereira AC
Pharmacogenomics; 2015 Jul; 16(8):865-76. PubMed ID: 26050796
[TBL] [Abstract][Full Text] [Related]
20. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
